What is the True Solubility Advantage for Amorphous Pharmaceuticals? View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2000-04

AUTHORS

Bruno C. Hancock, Michael Parks

ABSTRACT

PURPOSE: To evaluate the magnitude of the solubility advantage for amorphous pharmaceutical materials when compared to their crystalline counterparts. METHODS: The thermal properties of several drugs in their amorphous and crystalline states were determined using differential scanning calorimetry. From these properties the solubility advantage for the amorphous form was predicted as a function of temperature using a simple thermodynamic analysis. These predictions were compared to the results of experimental measurements of the aqueous solubilities of the amorphous and crystalline forms of the drugs at several temperatures. RESULTS: By treating each amorphous drug as either an equilibrium supercooled liquid or a pseudo-equilibrium glass, the solubility advantage compared to the most stable crystalline form was predicted to be between 10 and 1,600 fold. The measured solubility advantage was usually considerably less than this, and for one compound studied in detail its temperature dependence was also less than predicted. It was calculated that even for partially amorphous materials the apparent solubility enhancement (theoretical or measured) is likely to influence in-vitro and in-vivo dissolution behavior. CONCLUSIONS: Amorphous pharmaceuticals are markedly more soluble than their crystalline counterparts, however, their experimental solubility advantage is typically less than that predicted from simple thermodynamic considerations. This appears to be the result of difficulties in determining the solubility of amorphous materials under true equilibrium conditions. Simple thermodynamic predictions can provide a useful indication of the theoretical maximum solubility advantage for amorphous pharmaceuticals, which directly reflects the driving force for their initial dissolution. More... »

PAGES

397-404

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/a:1007516718048

DOI

http://dx.doi.org/10.1023/a:1007516718048

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017094560

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10870982


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0306", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Physical Chemistry (incl. Structural)", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/03", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Chemical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemistry, Pharmaceutical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Crystallization", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pharmaceutical Preparations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Solubility", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "X-Ray Diffraction", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Pfizer Inc., 66340, Groton, Connecticut"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hancock", 
        "givenName": "Bruno C.", 
        "id": "sg:person.0636134005.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636134005.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.292545.d", 
          "name": [
            "Merck Frosst Canada & Co., Kirkland, Quebec, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Parks", 
        "givenName": "Michael", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1248/cpb.40.819", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001943385"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/js9601896", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003304858"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1012148910975", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004334367", 
          "https://doi.org/10.1023/a:1012148910975"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1248/cpb.29.2675", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006254374"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1248/cpb.28.2565", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006918382"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0378-5173(94)00132-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007131147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0378-5173(94)00132-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007131147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/js9602711", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009483654"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jps.2600520210", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013339430"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jps.3030490417", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014971630"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jps.2600680823", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015970972"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0378-5173(89)90346-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018397724"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0378-5173(89)90346-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018397724"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1248/cpb.35.2943", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018631636"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jps.2600560712", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021872779"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1248/cpb.33.3447", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023500622"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jps.2600831211", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031087388"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jps.2600580817", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032885912"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1015984310068", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035367161", 
          "https://doi.org/10.1023/a:1015984310068"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0928-0987(99)00043-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038207243"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1248/cpb.21.878", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041514842"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0378-5173(84)90119-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046601101"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0378-5173(84)90119-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046601101"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jps.2600801016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047355191"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0099-5428(08)60192-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048885488"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1016241927429", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052880519", 
          "https://doi.org/10.1023/a:1016241927429"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/j150291a008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055688129"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jp983964+", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056129163"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jp983964+", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056129163"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1063/1.1749540", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1057811535"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1248/yakushi1947.95.6_629", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1075173731"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2000-04", 
    "datePublishedReg": "2000-04-01", 
    "description": "PURPOSE: To evaluate the magnitude of the solubility advantage for amorphous pharmaceutical materials when compared to their crystalline counterparts.\nMETHODS: The thermal properties of several drugs in their amorphous and crystalline states were determined using differential scanning calorimetry. From these properties the solubility advantage for the amorphous form was predicted as a function of temperature using a simple thermodynamic analysis. These predictions were compared to the results of experimental measurements of the aqueous solubilities of the amorphous and crystalline forms of the drugs at several temperatures.\nRESULTS: By treating each amorphous drug as either an equilibrium supercooled liquid or a pseudo-equilibrium glass, the solubility advantage compared to the most stable crystalline form was predicted to be between 10 and 1,600 fold. The measured solubility advantage was usually considerably less than this, and for one compound studied in detail its temperature dependence was also less than predicted. It was calculated that even for partially amorphous materials the apparent solubility enhancement (theoretical or measured) is likely to influence in-vitro and in-vivo dissolution behavior.\nCONCLUSIONS: Amorphous pharmaceuticals are markedly more soluble than their crystalline counterparts, however, their experimental solubility advantage is typically less than that predicted from simple thermodynamic considerations. This appears to be the result of difficulties in determining the solubility of amorphous materials under true equilibrium conditions. Simple thermodynamic predictions can provide a useful indication of the theoretical maximum solubility advantage for amorphous pharmaceuticals, which directly reflects the driving force for their initial dissolution.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1023/a:1007516718048", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094644", 
        "issn": [
          "0724-8741", 
          "1573-904X"
        ], 
        "name": "Pharmaceutical Research", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "17"
      }
    ], 
    "name": "What is the True Solubility Advantage for Amorphous Pharmaceuticals?", 
    "pagination": "397-404", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "51721a8dded00e2712ee2f58bf8d08824db7db72c40416936c935dcf5f6e458b"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10870982"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8406521"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/a:1007516718048"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017094560"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/a:1007516718048", 
      "https://app.dimensions.ai/details/publication/pub.1017094560"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T21:34", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8687_00000499.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1023/A:1007516718048"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1007516718048'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1007516718048'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1007516718048'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1007516718048'


 

This table displays all metadata directly associated to this object as RDF triples.

181 TRIPLES      21 PREDICATES      61 URIs      26 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/a:1007516718048 schema:about N2337bb7987304146bf7c09d7df04f14c
2 N8642d589d9f5464e82231d36dde83729
3 N880cb129561c44a685f6d8881002fc44
4 Nddf12ce75f9248dcb2c0a4e40cc714c4
5 Nebd4509a09ec48aeafd131eb1e4abbd9
6 anzsrc-for:03
7 anzsrc-for:0306
8 schema:author Ndc0a6b144aa34feb8d667c02d7fda29a
9 schema:citation sg:pub.10.1023/a:1012148910975
10 sg:pub.10.1023/a:1015984310068
11 sg:pub.10.1023/a:1016241927429
12 https://doi.org/10.1002/jps.2600520210
13 https://doi.org/10.1002/jps.2600560712
14 https://doi.org/10.1002/jps.2600580817
15 https://doi.org/10.1002/jps.2600680823
16 https://doi.org/10.1002/jps.2600801016
17 https://doi.org/10.1002/jps.2600831211
18 https://doi.org/10.1002/jps.3030490417
19 https://doi.org/10.1016/0378-5173(84)90119-4
20 https://doi.org/10.1016/0378-5173(89)90346-3
21 https://doi.org/10.1016/0378-5173(94)00132-4
22 https://doi.org/10.1016/s0099-5428(08)60192-6
23 https://doi.org/10.1016/s0928-0987(99)00043-3
24 https://doi.org/10.1021/j150291a008
25 https://doi.org/10.1021/jp983964+
26 https://doi.org/10.1021/js9601896
27 https://doi.org/10.1021/js9602711
28 https://doi.org/10.1063/1.1749540
29 https://doi.org/10.1248/cpb.21.878
30 https://doi.org/10.1248/cpb.28.2565
31 https://doi.org/10.1248/cpb.29.2675
32 https://doi.org/10.1248/cpb.33.3447
33 https://doi.org/10.1248/cpb.35.2943
34 https://doi.org/10.1248/cpb.40.819
35 https://doi.org/10.1248/yakushi1947.95.6_629
36 schema:datePublished 2000-04
37 schema:datePublishedReg 2000-04-01
38 schema:description PURPOSE: To evaluate the magnitude of the solubility advantage for amorphous pharmaceutical materials when compared to their crystalline counterparts. METHODS: The thermal properties of several drugs in their amorphous and crystalline states were determined using differential scanning calorimetry. From these properties the solubility advantage for the amorphous form was predicted as a function of temperature using a simple thermodynamic analysis. These predictions were compared to the results of experimental measurements of the aqueous solubilities of the amorphous and crystalline forms of the drugs at several temperatures. RESULTS: By treating each amorphous drug as either an equilibrium supercooled liquid or a pseudo-equilibrium glass, the solubility advantage compared to the most stable crystalline form was predicted to be between 10 and 1,600 fold. The measured solubility advantage was usually considerably less than this, and for one compound studied in detail its temperature dependence was also less than predicted. It was calculated that even for partially amorphous materials the apparent solubility enhancement (theoretical or measured) is likely to influence in-vitro and in-vivo dissolution behavior. CONCLUSIONS: Amorphous pharmaceuticals are markedly more soluble than their crystalline counterparts, however, their experimental solubility advantage is typically less than that predicted from simple thermodynamic considerations. This appears to be the result of difficulties in determining the solubility of amorphous materials under true equilibrium conditions. Simple thermodynamic predictions can provide a useful indication of the theoretical maximum solubility advantage for amorphous pharmaceuticals, which directly reflects the driving force for their initial dissolution.
39 schema:genre research_article
40 schema:inLanguage en
41 schema:isAccessibleForFree false
42 schema:isPartOf N8914a0762e324566b49ece1133fc93ec
43 N97511064b59442d9b2f606c675897b5a
44 sg:journal.1094644
45 schema:name What is the True Solubility Advantage for Amorphous Pharmaceuticals?
46 schema:pagination 397-404
47 schema:productId N3004e9dc25804c8a9f212625b9593514
48 N53ae1da1d20a4b968eab9e9aefffafa8
49 N6a14f6f79b5a4c879845a87cc9eac4b5
50 N95af824b40314f37ac64f516199aad18
51 Nfc686214dae94a3e80405eea8cc9021f
52 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017094560
53 https://doi.org/10.1023/a:1007516718048
54 schema:sdDatePublished 2019-04-10T21:34
55 schema:sdLicense https://scigraph.springernature.com/explorer/license/
56 schema:sdPublisher N64a149b529f34c55b67f741a06869830
57 schema:url http://link.springer.com/10.1023/A:1007516718048
58 sgo:license sg:explorer/license/
59 sgo:sdDataset articles
60 rdf:type schema:ScholarlyArticle
61 N2337bb7987304146bf7c09d7df04f14c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name X-Ray Diffraction
63 rdf:type schema:DefinedTerm
64 N3004e9dc25804c8a9f212625b9593514 schema:name readcube_id
65 schema:value 51721a8dded00e2712ee2f58bf8d08824db7db72c40416936c935dcf5f6e458b
66 rdf:type schema:PropertyValue
67 N37421fb59b4f41b4bd2d4384bf9f8c42 rdf:first Nb80f1227762e42f887939afab90cc872
68 rdf:rest rdf:nil
69 N53ae1da1d20a4b968eab9e9aefffafa8 schema:name nlm_unique_id
70 schema:value 8406521
71 rdf:type schema:PropertyValue
72 N5cdc342ccf744ba090a3e2bd1bc899bd schema:name Pfizer Inc., 66340, Groton, Connecticut
73 rdf:type schema:Organization
74 N64a149b529f34c55b67f741a06869830 schema:name Springer Nature - SN SciGraph project
75 rdf:type schema:Organization
76 N6a14f6f79b5a4c879845a87cc9eac4b5 schema:name dimensions_id
77 schema:value pub.1017094560
78 rdf:type schema:PropertyValue
79 N8642d589d9f5464e82231d36dde83729 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Pharmaceutical Preparations
81 rdf:type schema:DefinedTerm
82 N880cb129561c44a685f6d8881002fc44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Solubility
84 rdf:type schema:DefinedTerm
85 N8914a0762e324566b49ece1133fc93ec schema:issueNumber 4
86 rdf:type schema:PublicationIssue
87 N95af824b40314f37ac64f516199aad18 schema:name doi
88 schema:value 10.1023/a:1007516718048
89 rdf:type schema:PropertyValue
90 N97511064b59442d9b2f606c675897b5a schema:volumeNumber 17
91 rdf:type schema:PublicationVolume
92 Nb80f1227762e42f887939afab90cc872 schema:affiliation https://www.grid.ac/institutes/grid.292545.d
93 schema:familyName Parks
94 schema:givenName Michael
95 rdf:type schema:Person
96 Ndc0a6b144aa34feb8d667c02d7fda29a rdf:first sg:person.0636134005.91
97 rdf:rest N37421fb59b4f41b4bd2d4384bf9f8c42
98 Nddf12ce75f9248dcb2c0a4e40cc714c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Crystallization
100 rdf:type schema:DefinedTerm
101 Nebd4509a09ec48aeafd131eb1e4abbd9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Chemistry, Pharmaceutical
103 rdf:type schema:DefinedTerm
104 Nfc686214dae94a3e80405eea8cc9021f schema:name pubmed_id
105 schema:value 10870982
106 rdf:type schema:PropertyValue
107 anzsrc-for:03 schema:inDefinedTermSet anzsrc-for:
108 schema:name Chemical Sciences
109 rdf:type schema:DefinedTerm
110 anzsrc-for:0306 schema:inDefinedTermSet anzsrc-for:
111 schema:name Physical Chemistry (incl. Structural)
112 rdf:type schema:DefinedTerm
113 sg:journal.1094644 schema:issn 0724-8741
114 1573-904X
115 schema:name Pharmaceutical Research
116 rdf:type schema:Periodical
117 sg:person.0636134005.91 schema:affiliation N5cdc342ccf744ba090a3e2bd1bc899bd
118 schema:familyName Hancock
119 schema:givenName Bruno C.
120 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636134005.91
121 rdf:type schema:Person
122 sg:pub.10.1023/a:1012148910975 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004334367
123 https://doi.org/10.1023/a:1012148910975
124 rdf:type schema:CreativeWork
125 sg:pub.10.1023/a:1015984310068 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035367161
126 https://doi.org/10.1023/a:1015984310068
127 rdf:type schema:CreativeWork
128 sg:pub.10.1023/a:1016241927429 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052880519
129 https://doi.org/10.1023/a:1016241927429
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1002/jps.2600520210 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013339430
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1002/jps.2600560712 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021872779
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1002/jps.2600580817 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032885912
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1002/jps.2600680823 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015970972
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1002/jps.2600801016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047355191
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1002/jps.2600831211 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031087388
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1002/jps.3030490417 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014971630
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1016/0378-5173(84)90119-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046601101
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1016/0378-5173(89)90346-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018397724
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1016/0378-5173(94)00132-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007131147
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1016/s0099-5428(08)60192-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048885488
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1016/s0928-0987(99)00043-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038207243
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1021/j150291a008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055688129
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1021/jp983964+ schema:sameAs https://app.dimensions.ai/details/publication/pub.1056129163
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1021/js9601896 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003304858
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1021/js9602711 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009483654
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1063/1.1749540 schema:sameAs https://app.dimensions.ai/details/publication/pub.1057811535
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1248/cpb.21.878 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041514842
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1248/cpb.28.2565 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006918382
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1248/cpb.29.2675 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006254374
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1248/cpb.33.3447 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023500622
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1248/cpb.35.2943 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018631636
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1248/cpb.40.819 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001943385
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1248/yakushi1947.95.6_629 schema:sameAs https://app.dimensions.ai/details/publication/pub.1075173731
178 rdf:type schema:CreativeWork
179 https://www.grid.ac/institutes/grid.292545.d schema:alternateName Merck (Canada)
180 schema:name Merck Frosst Canada & Co., Kirkland, Quebec, Canada
181 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...